About the Company:
Chandra Bhagat Pharma Ltd is engaged in the business of marketing pharmaceutical critical care & health care products.
Company has obtained necessary approvals from FDA for getting the formulations manufacture from contract manufacturers on Loan license or on principle to principle basis.
Company has wide range of products portfolio of pharmaceutical formulation including IV & IM range Injections, few tablets to cater the Domestic & Export Market.
Company has established presence in major therapeutic categories for formulations such as Anti-cancer (Oncology), Antibiotics, Anesthesia, Hormones, Orthopedic, Cardiac, Cardiovascular, Anti-fungal, Antiviral, Pediatrics, Cardiology, Nephrology, Neurology etc.
Company is also engaged in promoting and marketing of Active Pharmaceuticals Ingredients (API’s) in India.
company also supplies pharmaceutical formulation under own brand name through own sales and distribution team.
Company’s core business is in marketing of Pharmaceutical formulation under IV (Intravenous) and IM (Intramuscular) – Injection, capsule and tablets to cater the multi-specialty hospitals, Government hospitals and nursing homes.
Contract Manufacturing Agreement:
Company has Contract Manufacturing Agreement with 4 pharmaceutical companies/entities. Company has maintained relationship with the regular suppliers having FDA and WHO approved plant to supply pharma formulations.
These units manufacture IV, tablets, capsules, dry powder, dry injections powder, liquids, Injections & dry injections under our own brands.
Wide Products Range:
Company has launched wide products range in pharma formulation having Trademarks such as Tigemor, Uroprase, Oncoginase and many more and established goodwill for quality products and have the regular clients for the same.
company also supply generic pharmaceutical formulation as – Make to order – for bulk supply to hospital, Health Centre of Corporate, Municipality and also for exports.
Supply and Distribution Agreement.
Company has entered into a supply and distribution agreement with Sinopharm India Private Limited, a subsidiary company of China National Pharmaceutical Group for importing the vaccines known as “HEPATITIS A (HepA)”.
Company has conducted clinical trials of HepA Vaccine for DCGI Approvals. As per letter dated October 1, 2019, the application is under review with Director General of Health Services Central Drugs standard Control Organization.
On receipt of approval, company will proceed for commercial launch of HepA Vaccine after clinical trial.
- Mr. Hemant Chandravadan Bhagat (Designation: Chairman Cum Managing Director)
- Mr. Pranav Hemant Bhagat (Designation: Whole-Time Director)
Financials of the Company:
|(in Crores)||FY 17||FY 18||FY 19||30th July 19|
Valuation of Peer Group Companies:
|Company Name||Face Value||EPS||PE Ratio||RoNW||NAV|
|Chandra Bhagat Pharma Ltd||10||1.17||43.59||4.71%||32.41|
|Earum Pharmaceuticals Ltd||10||53.83||0.84||27.95%||192.67|
|Vaishali Pharma Ltd||10||1.08||24.12||3.73%||32.47|
|Issue Opens on||31st January 2020|
|Issue Closes on:.||6th February 2020|
|Issue Size||Rs.10.2 cr|
|Market Cap||Rs.38.47 cr|
|Listing at||BSE SME|
|Equity Shares Offered (Fresh)||20,00,000|
|Equity Shares Prior to the Issue||55,45,056|
|Equity Shares after the Issue||75,45,056|
|Finalization of Basis of Allotment||on or Before 11th February 2020|
|Initiation of Refunds||on or Before 13th February 2020|
|Credit of Equity Shares:||on or Before 13th February 2020|
|Listing Date:||on or Before 14th February 2020|
IPO Valuation Parameters:
|Earnings Per Share (EPS)||Price To Earnings ratio (PE)||Return on Net Worth (RoNW)||Net Asset Value (NAV)|
|Check IPO Allotment Status:|
Link InTime Website (Click on the below Link)
|Company Contact Info:|
|Chandra Bhagat Pharma Limited
323-F Bhagat Bhuvan, Dr. Ambedkar Road,
Matunga (East), Mumbai- 400019;
Telephone No.: +91 22 2414 6154;
Web site: www.cbcpharma.com
|IPO Registrar Info:|
|LINK INTIME INDIA PRIVATE LIMITED
SEBI Registration Number: INR000004058
Address: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai – 400 083, Maharashtra
Tel. Number: +91 22 4918 6200
Email Id: firstname.lastname@example.org
|Lead Manager to the Issue:|
|BEELINE BROKING LIMITED
SEBI Registration Number: INM000012546
Address: 807, Phoenix Tower,
Opp. New Girish Cold Drinks, Near
Vijay Cross Roads, Navrangpura, Ahmedabad – 380 009
Telephone Number:+91 79 4840 5357